Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013 Financial Results on May 10

TARRYTOWN, N.Y., May 6, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss financial results for the first quarter 2013 on Friday, May 10, 2013 at 8:30 a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 68711767. A live webcast will be available on the Events section of the Progenics website, www.progenics.com, and a replay will be available on the website for two weeks.

Progenics Pharmaceuticals, Inc. discovers and develops innovative medicines for oncology, with a pipeline that includes product candidates in preclinical through late-stage development. Progenics' first commercial product, Relistor^® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. For additional information, please visit www.progenics.com.

(PGNX-G)

CONTACT: Amy Martini
         Corporate Affairs
         (914) 789-2816
         amartini@progenics.com
         
         Kathleen Fredriksen
         Corporate Development
         (914) 789-2871
         kfredriksen@progenics.com